Presentation of preclinical data on its BET BD1 program at Discovery on Target 2016

Stockholm, 16 September 2016 . Nuevolution AB (publ) (NUE.ST) will present preclinical data data from its BET BD1 program at Discovery on Target 2016 (DoT 2016) in Boston, MA, USA, on 20 and 22 September.

The oral presentation by Jimmi G. Seitzberg, Project Manager, Nuevolution, is titled “NUE7770 - A BET-BD1 selective chemical probe with potent cellular and in vivo anti-inflammatory activity”. The poster will be available for attendants of the symposium on Tuesday 20 September and is to be made available on www.nuevolution.com on the same day. On Thursday 22 September, Mr. Seitzberg will give a 20-minute oral presentation of the data.

NUE7770 is currently being tested in mouse models of Systemic Lupus Erythematosus (SLE) and Idiopathic Lung Fibrosis (IPF), severe inflammatory diseases.

For more information, please contact:

Thomas Franch, CSO

Phone: +45 7020 0987

Email: tf@nuevolution.com

Henrik D. Simonsen, CFO

Phone: +45 3913 0947

Email: hs@nuevolution.com

About bromodomain proteins

BET bromodomain proteins play an important role in regulation of gene expression, which thereby affect inflammatory responses and the ability of cancer cells to sustain growth and survive. The human proteome comprises 46 bromodomain-containing proteins, many of which are thought to be involved in cancer, inflammation and cardiovascular disease.


About Nuevolution

Nuevolution AB (publ) is a leading small molecule drug discovery biotech company founded in 2001, headquartered in Copenhagen, Denmark. Nuevolution partners its proprietary discovery platform and programs with pharmaceutical and biotechnology companies to seek future benefit of patients in need of novel medical treatment options. Nuevolution’s internal programs are focused on therapeutically important targets within inflammation, oncology and immuno-oncology.

Nuevolution AB (publ) is required to disclose the information provided herein pursuant to the Securities Markets Act. The information was sent for publication on Friday 16 September 2016, 13:00 (CEST).

Nuevolution AB (publ) is listed at Nasdaq First North Premier in Stockholm, Sweden (ticker: NUE.ST). Västra Hamnen Corporate Finance AB acts as Certified Adviser to Nuevolution AB (publ). More information about Nuevolution can be found on: www.nuevolution.com

Tags:

About Us

Nuevolution is a biotechnology company with a unique business model, where continuous revenue generation and risk mitigation represent primary objectives. This strategy is executed by a “multiple shots at goal” approach in combination with reduced research costs, where simultaneous development of multiple programs in parallel is made possible. Nuevolution is the inventor of Chemetics®. Chemetics® is a patent protected drug discovery research platform, which enables identification of small molecule (tablet based) drug candidates much more effectively and at lower cost than what is possible by other conventional methods. Nuevolution applies its research platform for the identification and development of its own pipeline of drug candidates for treatment of cancer and chronic inflammatory diseases Nuevolution applies a business model that is unique for a biotechnology company with a primary focus on revenue generation and risk minimization (i.e. lower cost development) by having a number of programs developed in parallel. Nuevolution is the inventor of Chemetics® , a patent protected drug discovery platform which enables efficient discovery of novel chemical small molecule leads for specific indications addressing disease targets within the company’s therapeutic focus areas

Subscribe

Documents & Links